GlassScriptPhysician profile
Robert Gemayel
NPI 1477244895
$644.32
in general payments reported to CMS, 2019-2025
14 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $229 · 2024: $129 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $161.47 | 2023-2025 | |
| Cardiva Medical, INC. | $117.88 | 2023 | Cardiva Vascade 6/7f Vcs |
| Emd Serono, INC. | $95.87 | 2025 | |
| Lilly USA, LLC | $56.66 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Actelion Pharmaceuticals US, INC. | $48.44 | 2023-2025 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, LTD. | $27.37 | 2023 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $23.01 | 2025 | Ultomiris |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.82 | 2024-2025 | Lifevest |
| Xeris Pharmaceuticals, INC. | $16.79 | 2024 | Gvoke Hypopen |
| Kiniksa Pharmaceuticals International, Plc | $15.57 | 2024 | Arcalyst |
| Jazz Pharmaceuticals INC. | $15.14 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.94 | 2024 | |
| Coopersurgical, INC. | $14.78 | 2024 | Paragard T 380a |
| Genzyme Corporation | $14.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gemayel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.